Publication at Faculty of Medicine in Hradec Králové |
2012
Abstract
The maintenance therapy with anti-CD20 monoclonal antibody, rituximab, represents one of the options how to extend disease-free interval in lymphoma patients. The aim of this article is to summarize information about the rituximab maintenance therapy of lymphoma, with respect to the current approved indications as well as to future directions, including potentially risks of this approach.